Australia Diabetes Drugs Market Analysis

Australia Diabetes Drugs Market Analysis


$ 3999

The Australia diabetes drugs market size was valued at $0.74 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $1.33 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Australia diabetes drug market will grow because of the high prevalence of diabetes in the country, which creates a significant demand for medications to manage the disease. The key market players are CSL Limited, AstraZeneca, Novo Nordisk, Sanofi, and others.

ID: IN10AUPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Chandani Patel

Buy Now

Australia Diabetes Drugs Market Executive Summary

The Australia diabetes drugs market size was valued at $0.74 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $1.33 Bn in 2030. As of 2021, Australia's GDP (Gross Domestic Product) was approximately US$1.4 trillion, making it the 13th largest economy in the world. The country has a highly developed market economy with a strong focus on services and industries such as mining, agriculture, and finance. Australia also has a strong healthcare system and invests a significant amount of its GDP in healthcare. In 2019-2020, total healthcare expenditure in Australia was $142 Bn. This represents around 10% of the country's GDP, which is similar to other high-income countries. The majority of healthcare expenditure in Australia is funded by the government, with the remaining costs being covered by private health insurance and out-of-pocket expenses by individuals. The government provides funding for a range of healthcare services, including hospital care, primary care, and pharmaceuticals.

The prevalence of diabetes in Australia is relatively high, with approximately 1.7 Mn people living with the disease in 2021. This represents around 7.3% of the population. The majority of these cases are type 2 diabetes, which is often linked to lifestyle factors such as obesity, physical inactivity, and poor diet.

The impact of diabetes on the drugs market in Australia is significant, as there is a high demand for medications to manage the disease. The market for diabetes drugs in Australia is large and growing, with a range of treatments available including oral medications, injectable medications, and insulin products. One factor driving growth in the diabetes drugs market in Australia is the aging population, as older adults are at increased risk for developing diabetes. In addition, rising rates of obesity and other lifestyle-related risk factors are contributing to an increase in the number of people living with diabetes in the country.

As the prevalence of diabetes in Australia is a significant public health concern, the demand for diabetes drugs has created opportunities for pharmaceutical companies and healthcare providers. However, it will be important to address issues related to cost and access to ensure that all patients can access the treatments they need to manage their diabetes effectively.

australia diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

The diabetes drugs market in Australia is driven by a combination of factors. One of the primary drivers is the high prevalence of diabetes in the country, which creates a significant demand for medications to manage the disease. According to the Australian Institute of Health and Welfare, approximately 1.7 million Australians were living with diabetes in 2021. This represents around 7.3% of the population, and the majority of cases are type 2 diabetes. The aging population and rising rates of obesity and other lifestyle-related risk factors are contributing to the growing number of people living with diabetes in the country, which is expected to drive continued growth in the market for diabetes drugs.

Moreover, in Australia is the availability of innovative treatments. Pharmaceutical companies are investing in research and development to create new and more effective treatments for diabetes. In recent years, there have been a number of new medications approved for use in Australia, including oral medications, injectable medications, and insulin products. These new treatments provide patients with more options for managing their diabetes, which can help to improve outcomes and quality of life.

Market Restraints

In Australia, one key market barrier is the high cost of these medications, which can be a barrier for some patients who may struggle to afford them. The government and private health insurance providers in Australia provide some coverage for diabetes medications, but many patients still face out-of-pocket costs for their treatments. This can create disparities in access to care and may contribute to poor outcomes for some patients.

Furthermore, in Australia is the ongoing debate over the pricing and reimbursement of these medications. Pharmaceutical companies are seeking to recoup their investments in research and development by setting high prices for their drugs, but some stakeholders argue that these prices are too high and may be unsustainable in the long term. There have been ongoing discussions in Australia about the need for greater transparency and accountability in drug pricing and reimbursement to ensure that patients have access to the treatments they need at an affordable cost.

Competitive Landscape

Key Players

  • CSL Limited
  • AstraZeneca
  • Novo Nordisk
  • Sanofi
  • Johnson & Johnson
  • Abott
  • Bayer Pharmaceuticals
  • Merck
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Novartis
  • GlaxoSmithKline

Notable deals

December 2021: CSL Behring announced a strategic partnership with uniQure to develop gene therapies for patients with hemophilia B. While not specifically related to diabetes drugs, this deal highlights the ongoing interest and investment in gene therapies, which could have implications for the development of diabetes treatments in the future.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

In Australia, the regulation and reimbursement of diabetes drugs and treatments are overseen by the Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Scheme (PBS), respectively.

The TGA is responsible for evaluating and approving new diabetes drugs and treatments for safety, quality, and efficacy. Before a drug can be marketed and sold in Australia, it must go through a rigorous regulatory process that includes clinical trials and scientific evaluation. Once a diabetes drug is approved by the TGA, it may be listed on the PBS for reimbursement. The PBS is a government-funded program that subsidizes the cost of prescription drugs for eligible Australian residents. To be listed on the PBS, a drug must meet certain criteria, including cost-effectiveness and clinical effectiveness.

There are several types of diabetes drugs that are available in Australia, including insulin, oral medications, and injectable medications. The cost of these drugs can vary depending on the type of medication, the dosage, and the frequency of use. However, most diabetes medications are subsidized by the PBS, which means that eligible patients pay a reduced amount for their prescriptions. In addition to medications, there are also other diabetes treatments that may be covered by the PBS, such as blood glucose monitoring devices, insulin pumps, and continuous glucose monitoring systems.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

  • Injectable Drugs
    • Insulin Based Injectables
    • Non-insulin Based Injectables
      • Exenatide (Byetta)
      • Dulaglutide (Trulicity)
      • Semaglutide (Ozempic, Wegovy)
      • Liraglutide (`Saxenda, Victoza)
      • Lixisenatide (Adlyxin)
      • Pramlintide (Symlin)
      • Tirzepatide (Mounjaro)
      • Albiglutide (Tanzeum)
  • Oral Drugs
    • Biguanides - Metformin (Glucophage and Glucophase XR)
    • Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
    • Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
    • Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
    • Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
    • Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
    • Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
    • Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
    • Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
    • Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
    • Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

  • Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
  • Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
  • Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 17 March 2023
Updated by: Vidhi Upadhyay

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up